Loading…
Haier Group plans to merge its subsidiary Haier Biomedical with RAAS Blood Products, a major plasma-derived products producer, through a share issuance. The merger aims to create a leading biotechnology company.
“Through this merger, Haier Biomedical aims to optimize its blood products industrial portfolio while capitalizing on synergies with RAAS to create a biotech company with sustainable growth potential.”www2.yicaiglobal.com
Summarized from public sources; check the original articles before acting on it.